SCHEMBL3312658

SCHEMBL3312658

COc1cc(CNS(=O)(=O)C(C)C)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.44
ALPL P05186 1/20 0.36
CYP1A1 P04798 1/20 0.33
HTR2A P28223 1/20 0.32
ERBB2 P04626 1/20 0.31
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE1C Q14123 1/20 0.31
P2RY2 P41231 2/20 0.31
P2RY4 P51582 2/20 0.31
IMPDH2 P12268 1/20 0.31
IMPDH1 P20839 1/20 0.31
KDM4E B2RXH2 2/20 0.31
POLB P06746 2/20 0.31
GRIA4 P48058 2/20 0.31
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2362967 0.89 CYP3A4 (0.50) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2352735 0.88 CYP3A4 (0.45) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL3313139 0.84 CYP3A4 (0.45) CYP3A4ALPLKDM4EMAPTMAPK1
SCHEMBL3313231 0.83 CYP3A4 (0.42) CYP3A4POLBMAPTMAPK1
SCHEMBL3314218 0.83 CYP3A4 (0.42) CYP3A4ALPLPOLBMAPTMAPK1
SCHEMBL2362843 0.81 CYP3A4 (0.48) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2348091 0.81 CYP3A4 (0.51) CYP3A4ALPLCYP1A1HTR2AKDM4E
SCHEMBL3308176 0.81 CYP3A4 (0.42) CYP3A4CYP1A1IMPDH2IMPDH1KDM4E
SCHEMBL3312623 0.80 CYP3A4 (0.44) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2363467 0.80 CYP3A4 (0.43) CYP3A4ALPLCYP1A1HTR2AERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885ALPL 4328/4885CYP1A1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.